<DOC>
	<DOCNO>NCT00003540</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness gemcitabine treat woman metastatic breast cancer previously treat doxorubicin paclitaxel .</brief_summary>
	<brief_title>Gemcitabine Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin Paclitaxel</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response rate gemcitabine woman metastatic breast cancer previously treat two four chemotherapy regimen , include doxorubicin paclitaxel . - Characterize nature toxicity gemcitabine patient population . - Determine response duration gemcitabine patient population . OUTLINE : Patients receive gemcitabine IV 30 minute weekly 3 consecutive week ( day 1 , 8 , 15 ) follow 1 week rest . Treatment continue every 4 week absence disease progression unacceptable toxic effect . Patients follow death . PROJECTED ACCRUAL : A total 14-30 patient accrue study within 13 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic breast cancer Bidimensionally measurable disease No bone scan abnormality alone Lytic lesion conjunction bone scan abnormality allow No pure blastic bone metastases No pleural peritoneal effusion No previously irradiate lesion Must receive 24 prior chemotherapy regimen , include paclitaxel doxorubicin , breast cancer Brain metastases allow measurable disease exist No uncontrolled life threaten brain lesion No carcinomatous meningitis Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : AST/ALT great 5 time upper limit normal Renal : Calcium great 11.0 mg/dL Other : Not pregnant Negative pregnancy test No history malignancy except carcinoma situ cervix curatively treat nonmelanoma skin cancer No serious medical illness , include severe infection severe malnutrition PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent chemotherapy Endocrine therapy : Prior hormonal therapy stage IV disease and/or adjuvant therapy allow At least 3 week since prior hormonal therapy Radiotherapy : See Disease Characteristics No prior radiotherapy great 30 % marrow bear bone At least 4 week since prior radiotherapy recover No concurrent radiotherapy measurable lesion Surgery : Recovered prior surgery No concurrent surgery measurable lesion Other : No concurrent nonprotocol treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>